Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LTA | P01374 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RAD1 | O60671 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985203 | 1.00 | MIF (0.54) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL5941069 | 0.91 | MIF (0.64) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL5941068 | 0.91 | MIF (0.64) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL4200596 | 0.86 | FBP1 (0.43) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL4200593 | 0.86 | FBP1 (0.43) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL14015554 | 0.84 | RELA (0.44) | MIFP2RY6CA1CA2KDM4E | |
| SCHEMBL5157555 | 0.84 | RELA (0.53) | HSD17B10KDM4EALDH1A1MAPTTDP1 | |
| SCHEMBL5157560 | 0.84 | RELA (0.53) | HSD17B10KDM4EALDH1A1MAPTTDP1 | |
| Bitoscanate SCHEMBL157128 | 0.84 | MIF (0.72) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL4195532 | 0.82 | RELA (0.59) | P2RY6KDM4EALDH1A1MAPTRELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906415-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INST NAT SANTE RECH MED (FR) | 2026-04-15 | — | — | EP | disclosed |
| US-12595517-B2 | Method to treat and stratify a patient suffering from a cancer | INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-04-07 | — | — | US | disclosed |
| US-20260035471-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INST NAT SANTE RECH MED (FR) | 2026-02-05 | — | — | US | disclosed |
| EP-4211273-B1 | METHOD TO TREAT AND STRATIFICATE A PATIENT SUFFERING FROM A CANCER | INST NAT SANTE RECH MED (FR) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025109147-A1 | METHOD TO PREDICT THE RISK OF A CARDIOVASCULAR EVENT IN A PATIENT WITH TYPE 2 DIABETES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-30 | — | — | WO | disclosed |
| US-12291752-B2 | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-05-06 | — | — | US | disclosed |
| WO-2025078632-A1 | METHODS OF PROGNOSIS AND TREATMENT OF PATIENTS SUFFERING FROM CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025073765-A1 | METHODS OF PROGNOSIS AND TREATMENT OF PATIENTS SUFFERING FROM MELANOMA | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025068340-A1 | METHOD TO PREDICT AML OUTCOME | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025045894-A1 | METHODS AND KITS FOR DIAGNOSING CAUSE OF NEPHROTIC SYNDROME AND GUIDING THERAPY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-03-06 | — | — | WO | disclosed |
| US-20070042386-A1 | Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system | NANOGEN, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2006011273-A1 | METHOD OF INHIBITING POSTISCHEMIC REPERFUSION-INDUCED CELL DEATH AND CELL DEATH INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-02-02 | — | — | WO | disclosed |
| US-6911310-B2 | Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system | NANOGEN, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-6906179-B2 | Antibody to SNIP1 | THE GENERAL HOSPITAL CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1067134-B1 | Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system | NANOTRONICS INC (US) | 2004-07-28 | — | — | EP | disclosed |
| US-6416953-B1 | BIOSENSOR COMPRISING PHOTONIC ENERGY SENSOR, POLYNUCLEOTIDE LINKED TO AT LEAST TWO DONOR CHROMOPHORES, SECOND POLYNUCLEOTIDE LINKED TO ACCEPTOR CHROMOPHORE POSITIONED BY LINKAGE AT DONOR-ACCEPTOR TRANSFER DISTANCE FROM DONOR | NANOGEN, INC. | 2002-07-09 | — | — | US | disclosed |
| US-6177259-B1 | SCREENING FOR INHIBITORS BY INCUBATING CASPASE, POLYGLUTAMINE PEPTIDE, AND CANDIDATE WHERE REDUCTION IN COMPLEX FORMATION INDICATES INHIBITOR; TREATMENT OF NERVOUS SYSTEM DISORDERS SUCH AS HUNTINGTON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2001-01-23 | — | — | US | disclosed |
| EP-0620822-A4 | HYBRIDIZATION OF POLYNUCLEOTIDES CONJUGATED WITH CHROMOPHORES AND FLUOROPHORES TO GENERATE DONOR-TO-DONOR ENERGY TRANSFER SYSTEM. | NANOTRONICS INC (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0620822-A1 | HYBRIDIZATION OF POLYNUCLEOTIDES CONJUGATED WITH CHROMOPHORES AND FLUOROPHORES TO GENERATE DONOR-TO-DONOR ENERGY TRANSFER SYSTEM | NANOTRONICS, INC. (US) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993009128-A1 | HYBRIDIZATION OF POLYNUCLEOTIDES CONJUGATED WITH CHROMOPHORES AND FLUOROPHORES TO GENERATE DONOR-TO-DONOR ENERGY TRANSFER SYSTEM | NANOTRONICS, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595517-B2 | Method to treat and stratify a patient suffering from a cancer | PDCD1, CD274, PDCD4 | MIF 1237/4885P2RY6 2809/4885CA1 3206/4885 |
| US-20260035471-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | CD274, PDCD1LG2, PDCD1 | MIF 2365/4885P2RY6 2730/4885CA1 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.